Mr. Kishbauch was elected to the Board in September 2013.  He has held senior management positions in the life sciences industry for almost three decades, with extensive operational, strategic, product planning and promotion, sales, marketing and product launch experience. Mr. Kishbauch was most recently President and Chief Executive Officer of Achillion Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2004 until his retirement in 2013. Prior to his work at Achillion, Mr. Kishbauch founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercial-stage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson & Johnson in 2003. He has previously held senior management positions with MedImmune, Inc .  Mr. Kishbauch continues to serve on Achillion’s board as a member of the Compliance Committee and currently serves on the Board as well as the Compensation and Audit Committees of Catabasis Pharmaceuticals, Inc., also a publicly traded biopharmaceutical company. He was a director of ARIAD Pharmaceuticals, Inc. from 2004 to 2008 and has held board positions with several other life sciences companies. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. Mr. Kishbauch was elected to the Board in September 2013.  He has held senior management positions in the life sciences industry for almost three decades, with extensive operational, strategic, product planning and promotion, sales, marketing and product launch experience. Mr. Kishbauch was most recently President and Chief Executive Officer of Achillion Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from 2004 until his retirement in 2013. Prior to his work at Achillion, Mr. Kishbauch founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercial-stage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson & Johnson in 2003. He has previously held senior management positions with MedImmune, Inc .  Mr. Kishbauch continues to serve on Achillion’s board as a member of the Compliance Committee and currently serves on the Board as well as the Compensation and Audit Committees of Catabasis Pharmaceuticals, Inc., also a publicly traded biopharmaceutical company. He was a director of ARIAD Pharmaceuticals, Inc. from 2004 to 2008 and has held board positions with several other life sciences companies. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.

Marketing